An Open-label, Parallel-group, Single-dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Subcutaneous Epratuzumab in Healthy Caucasian and Japanese Subjects

Trial Profile

An Open-label, Parallel-group, Single-dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Subcutaneous Epratuzumab in Healthy Caucasian and Japanese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2015

At a glance

  • Drugs Epratuzumab (Primary) ; Epratuzumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors UCB
  • Most Recent Events

    • 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 08 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top